U betcha, Doc. Panic breeds poverty ( or at least losses). Miami
With a parrot on his back...
Through bleary eyes he watches the business channel...
Suddenly, there's Dr Frost with a Mona Lisaesque smile;
Frost looks into the camera, as if directly at the s.b, and asks,
"Who Ya gonna believe?
Me or your lyin ' eyes? "
Overcome with paid posting nausea he falls to the floor with a "splat"....
(Further installments to come)
My current maid and I simply can't throw out the trash quickly enough. The upside is that even trash has its limits as we shall soon see. Long, stong and getting quite bored with all this short term absurdity.
It's amazing how many people forget that the market is risky and that you don't lose till you sell.....I can't time the market... maybe they are gypsies with crystal balls. Somehow I doubt that. LONG
YES, and why would he want to scoop up more shares at these prices? Because it is a great deal! No one ever got rich buying proven products at their price zenith. What's going on is a lot of cow chips that will pass....sooner than some may think. Long
I like a man (I assume, if not, apologies) who puts his money where his mouth is. Most of these bozos have mouths in inverse proportion to their wallets. IMO Long
all this non-OPKO stuff would hit the fan at the same time is prevaricating. What's going to get hit the hardest...? The most speculative, of course. (i.e. bios) However, calm always prevails (unless the world ends) and that's when longs will be rewarded and many will kick themselves in the fanny for NOT following the lead of Frost and company. Obviously, I am LONG and CALM
OPKO is successfully performing on its business model with pipeline advancement, revenue generation and strategic investments.
According to estimates, it is expected to turn profitable by next year.
Multiple important catalysts approaching, including PDUFA date of Rolapitant, conferences, and trials.
Douglass: Yeah. It's interesting because they're going after all these drugs, and they have the 4Kscore prostate cancer test. I think one of things a lot of folks think when they look at Opko Health is, "How do those fit together?" Everything here seems different. It makes sense: If you can spend $1 to make $2, you should do it, but at the same time, it does feel a little scattered of a strategy with Opko. At least when I took a look at them it did. What's your take on that, Todd?
Campbell: Yeah. I think because of the thought of, "Let's get all these great ideas together and try to commercialize them," it creates the message that's a little muddy with Opko. As a result you have a lot of people who don't fully understand the story, and they're betting against the stock because they don't understand what the potential could be. I don't want to say that they're wrong to bet against it, but I think we need to remember that Frost has a history of being able to cobble together a lot of deals that are seemingly unconnected, and then be able to tie them up into a nice bow where they all dovetail very well together.
I think, in this case, he's building himself a franchise of drugs that are serving under-penetrated markets, or markets that need innovation, and by buying BioReference Labs and getting them a very large network of deals with health insurers and other payers, he's strengthening the ability to go out and not only get these drugs into the market, but commercialize them effectively. One of the things I think is really important about this most recent deal with BioReference Labs isn't how it relates to other drugs -- like the human growth hormone -- it's more, "How will it benefit his 4Kscore prostate cancer test?"
The Motley Fool has many subscribers and I must say the statement that the POC market could reach $19.3 billion by 2018 is astounding. Sure there's competition...as noted...but hey this is tremendous AND only one one gift in Santa Frost's bag of goodies...... Long